Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The new Oxford Lymphoid Disorder Study Group, chaired by Dr Graham Collins, will be launched this September in Blood Cancer Awareness Month

OLDSG Logo

The Oxford Lymphoid Disorder Study Group (OLDSG) will be introduced later this month at a virtual launch event being held on Friday 18 September 2020, 2 – 5 pm.

The group is led by Dr Graham Collins and a steering group, who will be helping to translate and direct lymphoid research in Oxford into patient-focused applications.

The upcoming event on 18 September 2020 falls within Blood Cancer Awareness Month in the UK, and will give those involved in various lymphoid disorder research the opportunity to talk more about their work and how it applies to diseases such as Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia.

You can sign up for this upcoming event and see the full agenda of talks from top clinicians and researchers in the lymphoid disorder sector, by clicking here.

About the OLDSG

At present, around 3-4% of people will develop either lymphoma or Chronic Lymphocytic Leukemia (CLL) during their lifetime. Together, lymphoma and CLL represent the commonest blood cancer by some margin.

The OLDSG acts as a network to bring together researchers and clinicians from across the University of Oxford and University Hospitals Trust. In doing so, the group hopes to:

  • to increase the visibility of lymphoid disorder research in the university
  • to foster collaborations between clinicians and laboratory-based scientists leading to high quality translational projects
  • to interact with patients and the public at all levels of project development to deliver research which impacts directly on patient need

For more information about the group and its members, please see the dedicated OLDSG page here.

Similar Stories

Public talk: Using blood tests to detect cancer

Organised by the NIHR Oxford Biomedical Research Centre, Professor Mark Middleton and patient representative Sue Duncombe discuss how cancer blood tests are being assessed and how they may change how cancer is diagnosed in the NHS.

Researchers make miniature ‘bone marrows in a dish’ to improve anti-cancer treatments

Scientists from the University of Oxford's MRC Weatherall Institute of Molecular Medicine and the University of Birmingham have made the first bone marrow ‘organoids’ that include all the key components of human marrow. This technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual cancer patients.

Profiling the entire cancer genome identifies new subgroups of blood cancer that can be used to predict likely clinical outcomes

The University of Oxford has led the largest and most comprehensive analysis of the entire genomic landscape of the commonest type of blood cancer called chronic lymphocytic leukaemia (CLL) as part of the UK’s 100,000 Genomes Project